We expect Vernalis to announce interim results to December 2015 on 17th March. This is the first set of results following the launch of Tuzistra into the $3.3bn prescription cough-cold market in September 2015. Although we do not expect Tuzistra sales in H1 2016 to be substantial we expect commentary around uptake to be the key driver of the shares. Our analysis suggests a successful launch now the flu season has commenced. We maintain our BUY and 91p target price.